OrbiMed's Stake in Q32 Bio Diluted to 15.4% Following Recent Offering

summarizeSummary

OrbiMed Advisors and OrbiMed Capital GP VII LLC reported a decrease in their beneficial ownership of Q32 Bio Inc. to 15.4% due to an increase in the company's outstanding shares, reflecting the dilutive impact of a recent capital raise.

check_boxKey Events

• Major Shareholder Stake Reduced

  OrbiMed Advisors and OrbiMed Capital GP VII LLC now beneficially own 2,252,987 shares, representing 15.4% of Q32 Bio Inc.'s common stock.

• Dilution from Recent Offering

  The decrease in percentage ownership is due to an increase in the total number of outstanding shares, resulting from the company's recent dilutive capital raise.

auto_awesomeAnalysis

This Schedule 13D/A filing updates OrbiMed's beneficial ownership in Q32 Bio Inc. The decrease in percentage ownership from an unspecified prior level to 15.4% is explicitly attributed to an increase in the number of outstanding shares, rather than a sale by OrbiMed. This change reflects the dilutive effect of the company's recent $10.5 million offering, which was reported in the 8-K and 10-K filings on March 10, 2026. While OrbiMed remains a significant shareholder, this passive dilution highlights the impact of the company's capital-raising activities on existing investor stakes.